Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

Harmony Biosciences (HRMY) reported Q1 2025 sales of $185 million, up 20% year-over-year, primarily driven by its narcolepsy drug Wakix, which currently accounts for all company revenue. The company's pipeline diversification includes ZYN-002, a synthetic CBD gel in a pivotal Phase III study for Fragile X Syndrome, with top-line data expected by September, representing a significant near-term catalyst and potential first-in-class therapy. Further pipeline assets, such as EPX-100 for rare epilepsies and next-generation Wakix formulations, are critical as Wakix faces exclusivity loss by the decade's end, positioning HRMY for continued growth in neuroscience despite recent stock underperformance.

Analysis

Harmony Biosciences (HRMY) presents a compelling, albeit high-risk, investment case centered on its strategic pivot from a single-product entity to a diversified neuroscience company. Currently, its entire revenue stream is derived from the narcolepsy drug Wakix, which demonstrated robust commercial performance with a 20% year-over-year sales increase to approximately $185 million in Q1 2025 and a full-year 2025 sales forecast of $820-$860 million. This financial strength, underscored by a $610 million cash balance, is crucial for funding its pipeline development ahead of Wakix's expected loss of exclusivity by the end of the decade. The most significant near-term catalyst is the top-line data from the Phase III RECONNECT study for ZYN-002, a synthetic CBD gel for Fragile X Syndrome, expected before the end of September. A positive outcome could establish a first-in-class therapy for a substantial patient population and validate the company's 2023 acquisition of Zynerba Pharmaceuticals. However, the stock's 7% year-to-date decline, underperforming the industry, reflects investor apprehension over pipeline execution risk and intense competition from established players like Jazz Pharmaceuticals (JAZZ) and Axsome Therapeutics (AXSM) in both sleep disorders and epilepsy.

Key Decisions for Investors

• Investors should closely monitor the upcoming Phase III RECONNECT study results for ZYN-002, due by the end of September, as this is the primary near-term catalyst with the potential to significantly de-risk the pipeline and re-rate the stock.
• While the pipeline holds future value, continued tracking of sales momentum for the flagship drug Wakix is essential, as its projected 18% midpoint revenue growth for 2025 funds the company's entire diversification strategy.
• Given the direct competition with Jazz Pharmaceuticals and Axsome Therapeutics, and a recent regulatory setback for Wakix in a secondary indication, positions in HRMY should be weighed against the inherent binary risks of clinical trial outcomes and the competitive landscape.